Does anyone have any insight on this group?
JPM is the undisputed leader in healthcare banking. Goldman isn't that strong in the space, from what I understand, nor are many of the other BB's. And then you have middle market firms like Jefferies, Cowen, Leerink that have good deal flow but don't have the BB brand name pulling for them.
Where does Morgan Stanley fit in - can anyone familiar with the group offer some insight? Thanks.
| +135 | If Tik Tok is forced to sell, what banks do you think would be involved in the deal? | 60 | 4h | |
| +49 | Intern Ettiquette | 14 | 18h | |
| +47 | Ranking banks that went under | 34 | 17h | |
| +42 | Relevance of A-Levels for U.K. London recruiting | 31 | 1h | |
| +39 | Burnt Out M&A ASO | 22 | 1d | |
| +33 | NEED NY RESTAURANT RECOMMENDATIONS | 23 | 15m | |
| +27 | 2024 new grads who didnt get return offers update | 12 | 1d | |
| +23 | PSA to gymcels: focus on the summer internship | 9 | 1d | |
| +23 | Would comitting to ATL İB be stupid? Please give feedback. | 15 | 7m | |
| +21 | IB Career Guideline | 12 | 6h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Bump
They were the sole advisor to Cigna in the Cigna-Express Scripts deal, so I think it's reasonable to conclude their healthcare team is pretty decent...
Lazard and Centerview were both on the Cigna/Express Scripts as well as the CVS/Aetna deal.
https://www.thomsonreuters.co.jp/content/dam/openweb/documents/pdf/japa…
Healthcare in the US 2017
1- GS ($126bn)
2- Barclays ($95bn)
3- Lazard ($85bn)
I don't know how students come here and say stuff like this without any regard for actual data. Who told you JPM was an "undisputed leader"? There are no undisputed leaders in IBD it's a very competitive market even holy GS only has 20% of market share in M&A. You should be more careful re soundbites
THANK YOU +++
JPM is definetely #1 in healthcare.....
Above ranking being based on deal size skews it. You can be a print advisor on a Pfizer deal and be sitting at $100bn+ league table cred.
Total fee (including Lev Fin and Equity) would put JPM on top. But they have lost some footing over last couple of years compared to say 2014. GS probably equally strong in M&A and equity. GS does very well with public company sell sides. Among BBs BAML and Barclays come next. MS does some big deals but is smaller / less volume. CS lost most of their guys but still shows up now and then. UBS rarely but sometimes. DB/(RBC/WF) non factors.
Among boutiques Lazard and Centerview gets most. Centerview got some GS/CS people recently and also have ex-ML people. Evercore, Guggenheim probably after that. You’ll find all these guys do deals based on their sub vertical focus / power MDs.
And if you want to pump out sponsor sell sides CIMs, can’t go wrong with Jefferies and Moelis. Would argue Jefferies does more deal than any of the above even. Harris Williams, William Blair, Houlihan Lokey does lot for the smaller sponsor sell sides.
Guggenheim was lead M&A counsel for the failed Allergan acquisition deal. Does that count for anything?
Vel voluptas ea reprehenderit magnam voluptatum odio possimus omnis. A non corrupti doloremque ex et dolores esse. Sint soluta quidem ipsa qui enim at dignissimos.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...